Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10576MR)

This product GTTS-WQ10576MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10576MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12732MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ6274MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ8921MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ12257MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ9143MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ987MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ14375MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ12181MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW